20 January 2021 - Sobi today announced that the European Commission has approved an extension of the indication for Doptelet (avatrombopag) to include the treatment of primary chronic immune thrombocytopenia in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) in all European Union member states.

In addition to current indications, the new indication reads; Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

Read Sobi press release